Last reviewed · How we verify

Epirubicin + ifosfamide + etoposide

European Lung Cancer Working Party · Phase 3 active Small molecule

Epirubicin + ifosfamide + etoposide is a Combination chemotherapy (anthracycline + alkylating agent + topoisomerase II inhibitor) Small molecule drug developed by European Lung Cancer Working Party. It is currently in Phase 3 development for Small cell lung cancer (phase 3 trial).

This combination chemotherapy regimen uses three cytotoxic agents that damage DNA and disrupt cell division to kill rapidly dividing cancer cells.

This combination chemotherapy regimen uses three cytotoxic agents that damage DNA and disrupt cell division to kill rapidly dividing cancer cells. Used for Small cell lung cancer (phase 3 trial).

At a glance

Generic nameEpirubicin + ifosfamide + etoposide
SponsorEuropean Lung Cancer Working Party
Drug classCombination chemotherapy (anthracycline + alkylating agent + topoisomerase II inhibitor)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Epirubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents strand separation. Ifosfamide is an alkylating agent that cross-links DNA strands, preventing replication. Etoposide is also a topoisomerase II inhibitor that stabilizes DNA-enzyme complexes. Together, these agents create multiple mechanisms of DNA damage to overcome cancer cell resistance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Epirubicin + ifosfamide + etoposide

What is Epirubicin + ifosfamide + etoposide?

Epirubicin + ifosfamide + etoposide is a Combination chemotherapy (anthracycline + alkylating agent + topoisomerase II inhibitor) drug developed by European Lung Cancer Working Party, indicated for Small cell lung cancer (phase 3 trial).

How does Epirubicin + ifosfamide + etoposide work?

This combination chemotherapy regimen uses three cytotoxic agents that damage DNA and disrupt cell division to kill rapidly dividing cancer cells.

What is Epirubicin + ifosfamide + etoposide used for?

Epirubicin + ifosfamide + etoposide is indicated for Small cell lung cancer (phase 3 trial).

Who makes Epirubicin + ifosfamide + etoposide?

Epirubicin + ifosfamide + etoposide is developed by European Lung Cancer Working Party (see full European Lung Cancer Working Party pipeline at /company/european-lung-cancer-working-party).

What drug class is Epirubicin + ifosfamide + etoposide in?

Epirubicin + ifosfamide + etoposide belongs to the Combination chemotherapy (anthracycline + alkylating agent + topoisomerase II inhibitor) class. See all Combination chemotherapy (anthracycline + alkylating agent + topoisomerase II inhibitor) drugs at /class/combination-chemotherapy-anthracycline-alkylating-agent-topoisomerase-ii-inhibitor.

What development phase is Epirubicin + ifosfamide + etoposide in?

Epirubicin + ifosfamide + etoposide is in Phase 3.

What are the side effects of Epirubicin + ifosfamide + etoposide?

Common side effects of Epirubicin + ifosfamide + etoposide include Myelosuppression (neutropenia, thrombocytopenia), Nausea and vomiting, Alopecia, Mucositis, Cardiotoxicity (epirubicin-related), Hemorrhagic cystitis (ifosfamide-related).

Related